Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2025
0mins
Source: Businesswire
Satellos Bioscience Participation: Satellos Bioscience Inc. will participate in the 2025 Parent Project Muscular Dystrophy Annual Conference in Las Vegas, focusing on improving outcomes for individuals with Duchenne muscular dystrophy and sharing updates on their muscle regeneration research.
Development of SAT-3247: The company is advancing SAT-3247, an innovative oral drug aimed at enhancing muscle repair by targeting a key protein, AAK1, to compensate for the absence of dystrophin in muscle stem cells, with potential applications in other muscle diseases as well.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
